➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Merck
Medtronic
Mallinckrodt
Moodys

Last Updated: October 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ELBASVIR; GRAZOPREVIR

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for elbasvir; grazoprevir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01717326 ↗ A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) Completed Merck Sharp & Dohme Corp. Phase 2 2013-02-01 This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12) in each of the treatment arms.
NCT01932762 ↗ Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) Completed Merck Sharp & Dohme Corp. Phase 2 2013-10-01 This is a multi-site, open-label trial evaluating the safety and efficacy of 100 mg of grazoprevir (MK-5172) used in combination with or without 50 mg of elbasvir (MK-8742) and/or ribavirin (RBV) in treating non-cirrhotic treatment-naïve participants with chronic genotype (GT) 2, 4, 5, and 6 hepatitis C infection. In Part A there is no randomization or stratification; all GT2 participants will be assigned to arm A1. In Part B, all GT2 participants will be assigned to Arm B1 and all participants with GT4, GT5 and GT6 will be randomized in a 1:1 ratio to either Arm 3 or Arm 4 with stratification by genotype.
NCT01937975 ↗ The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Completed Merck Sharp & Dohme Corp. Phase 1 2013-09-01 Grazoprevir (MK-5172) and Elbasvir (MK-8742) were studied as the principal components of combination oral therapy for hepatitis C virus (HCV). The study examined the pharmacokinetic (PK) profiles of Grazoprevir and Elbasvir following 10 days of dosing in participants with end stage renal disease (ESRD) on hemodialysis (HD) or participants with severe renal impairment. Both groups were compared to healthy matched controls.
NCT02092350 ↗ Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) Completed Merck Sharp & Dohme Corp. Phase 2/Phase 3 2014-03-01 This study will evaluate the safety and efficacy of combination treatment with grazoprevir (MK-5172) + elbasvir (MK-8742) for cirrhotic and non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV) infection and chronic kidney disease (CKD). The primary study hypothesis is that the proportion of HCV GT1-infected CKD participants within the Immediate Treatment and Intensive Pharmacokinetics (PK) groups achieving a sustained viral response 12 weeks after the end of all study treatment (SVR12) will be >45%.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for elbasvir; grazoprevir

Condition Name

Condition Name for elbasvir; grazoprevir
Intervention Trials
Hepatitis C 32
Chronic Hepatitis C 6
HIV 3
Hepatitis C, Chronic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for elbasvir; grazoprevir
Intervention Trials
Hepatitis C 53
Hepatitis 43
Hepatitis A 19
Hepatitis C, Chronic 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for elbasvir; grazoprevir

Trials by Country

Trials by Country for elbasvir; grazoprevir
Location Trials
United States 8
United Kingdom 3
Netherlands 3
Taiwan 3
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for elbasvir; grazoprevir
Location Trials
Pennsylvania 3
Massachusetts 2
California 1
Texas 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for elbasvir; grazoprevir

Clinical Trial Phase

Clinical Trial Phase for elbasvir; grazoprevir
Clinical Trial Phase Trials
Phase 4 19
Phase 3 19
Phase 2/Phase 3 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for elbasvir; grazoprevir
Clinical Trial Phase Trials
Not yet recruiting 25
Completed 16
Recruiting 8
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for elbasvir; grazoprevir

Sponsor Name

Sponsor Name for elbasvir; grazoprevir
Sponsor Trials
Merck Sharp & Dohme Corp. 39
University of Pennsylvania 3
Fundacion Clinic per a la Recerca Biomédica 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for elbasvir; grazoprevir
Sponsor Trials
Other 43
Industry 40
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Express Scripts
Moodys
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.